Little information is available on long-term immune reconstitution after therapy with alemtuzumab in B-CLL patients. We present long-term follow-up data for blood lymphocyte subsets analysed by flow cytometry in previously untreated B-CLL patients who received alemtuzumab subcutaneously as firstline therapy. All lymphoid subsets were significantly (Po0.001) and profoundly reduced; the median end-of-treatment counts þ and CD8 þ levels in blood had reached 4100 cells/ll in 450% of the patients at 4 months after the end of treatment. One patient had a cytomegalovirus reactivation and one patient developed Pneumocystis carinii pneumonia during therapy. No opportunistic or other major infections were recorded during unmaintained, long-term follow-up. There was no correlation between the cumulative dose of alemtuzumab and the severity or length of immunosuppression. CD52
Introduction
B-cell chronic lymphocytic leukaemia (B-CLL) is currently incurable with alkylating agent-based chemotherapy or purine analogs since, despite initial remissions, relapse ultimately occurs. [1] [2] [3] Hence, there is an urgent need for novel treatments for this disease.
The monoclonal antibody alemtuzumab (CamPath s ) has demonstrated encouraging results as a new agent in the treatment of B-CLL, both as a salvage therapy [4] [5] [6] and as firstline treatment. 7 Data from a recent pivotal clinical trial have established alemtuzumab as the standard of care in heavily pretreated, chemotherapy-refractory B-CLL patients. 5 Alemtuzumab is directed against the panlymphocyte marker CD52, which is found on mature B-and T-lymphocytes, natural killer (NK) cells and monocytes, but not on haematopoietic stem cells. 8 Granulocytes (495%) are CD52 À . CD52 is expressed abundantly on the malignant clone in B-CLL, and alemtuzumab is effective in clearing disease from blood and bone marrow. [5] [6] [7] In heavily pretreated patients, alemtuzumab is able to produce response rates of 33-43% 4-6 (Rai KR. Blood 2002; 100: 205a abstract), while in symptomatic but previously untreated patients, response rates of 480% can be achieved. 7, 9 Data on the long-term effects of alemtuzumab on lymphocyte subpopulations in B-CLL patients are limited. Subsets of interest include CD4
þ and CD8 þ T cells, CD3 À 56 þ NK cells and CD3
þ 56 þ NK-T cells, since their depletion may increase the susceptibility to opportunistic and other severe infections. It is also important to study granulocytes and monocytes following alemtuzumab treatment. The appearance in the blood of CD52 À T-cell subpopulations has been reported, but their time kinetics and functional capability are still unknown. [10] [11] [12] We have recently reported efficacy and safety results in patients with symptomatic B-CLL treated with subcutaneous (s.c.) alemtuzumab as first-line therapy. 9 Alemtuzumab was delivered over a prolonged treatment period of 18 weeks. In order to identify the long-term immunological effects, we present follow-up data on blood cell subsets in this patient cohort.
Patients and methods

Patients
Patients with B-CLL who received alemtuzumab s.c. as first-line treatment as part of a phase II clinical trial, 9 and for which at least two blood cell samples were analysed (before and after the end of therapy) were included in this immunological study. The design of the clinical study has been described previously. 9 Adults (between 18 and 75 years of age) were eligible for treatment if they had a diagnosis of B-CLL; a World Health Organisation performance status of p1; a life expectancy of X12 weeks; and were symptomatic, 13 required treatment and had not been treated previously. The exclusion criteria were: active infection; pregnancy or lactation; HIV-positive disease; autoimmune haemolysis or thrombocytopenia requiring treatment; or grade III or IV heart failure, according to the New York Heart Association functional classification.
In all, 10 aged-matched healthy donors (median age 64 years (range 59-77 years)) served as controls to determine the normal range of the lymphoid cell populations analysed by flow cytometry.
Treatment
The treatment schedule has been described previously. 9 Briefly, 3 mg of alemtuzumab was administered by s.c. injection in the thigh on Day 1. If well tolerated, this dose was increased to 10 mg on Day 3 and then to the target dose of 30 mg, divided between two injection sites (1.5 ml at each site), on Day 5. Dose escalation over a period of 1À2 weeks was used in the event of local skin erythema and/or oedema. After the dose-escalation phase and the disappearance of 'first-dose' skin reactions, the 30-mg dose was given three times weekly (t.i.w.) for a maximum of 18 weeks. If the treatment was interrupted for 47 days, the dose was reinitiated at 3 or 10 mg. The treatment was stopped in the event of patients having nonacceptable side-effects/toxicity, or if they achieved a complete remission (CR) or fulfilled the criteria for progressive disease (PD). Prophylactic medication against 'first-dose' reactions included paracetamol (1 g orally) and antihistamines (clemastine 2 mg intravenously), given 30 min before the injections. Once all 'first-dose' side effects had disappeared, clemastine and paracetamol prophylaxis was gradually withdrawn. Allopurinol (300 mg/day) was given for the first 4 weeks. Anti-infective prophylaxis, valaciclovir (500 mg tablets, twice daily), fluconazole (50 mg/day) and cotrimoxazole (twice daily, three times a week) was given during and for 8 weeks after the completion of treatment.
At enrolment, a complete examination was performed. This included the assessment of lymph node, liver, and spleen size, a computed tomography (CT) scan of the thorax and abdomen, and full laboratory analysis of blood parameters. Bone marrow aspiration and trephine biopsy were performed and immunophenotyping of B-CLL cells in blood or bone marrow (CD19/ CD5/CD23, CD19/CD5/CD52) was carried out by flow cytometry.
During treatment, blood counts and a differential were analysed once weekly and serum electrolytes were measured and serum liver tests performed every 3 weeks. Physical examination, including tumour assessment, chest and abdominal CT scan (if initially abnormal), bone marrow aspiration, and trephine biopsy were carried out every 6 weeks. At the completion of treatment, all the above tests were repeated. Flow cytometry was performed to verify morphologic CR in the bone marrow.
During unmaintained follow-up, physical examination including the assessment of lymph node, liver and spleen size was performed each month between months 2 and 6, and quarterly thereafter. Blood counts were analysed weekly for the first month, monthly during months 2-6 and quarterly thereafter. A chest and abdominal CT scan was performed twice yearly to a maximum of 2 years. The follow-up examinations were stopped if patients were diagnosed with PD. For patients in morphologic CR, bone marrow examination, including immunophenotyping, was repeated at 8 weeks after treatment and otherwise when clinically indicated.
Flow cytometry and immunophenotyping
All analyses were conducted on fresh cells. Baseline samples were collected within 1 week before the start of alemtuzumab therapy. Blood was collected in vacuum tubes with heparin as an anticoagulant. Whole blood (50 ml) was incubated for 15 min in the dark, at room temperature, with four prediluted triple combinations of monoclonal antibodies at the pretitrated optimal concentrations: The samples were washed and the erythrocytes were lysed with fluorescence-activated cell sorting (FACS)-lysing solution (BD).
Flow cytometry was performed using FACScan (BD) and 10 000 events were acquired. Cell-Quett (BD) software was used for acquisition and analysis. For analysis, the lymphocyte gate was set on forward-scatter/side-scatter plots, and the percentages of CD4
þ cells were recorded. The total numbers were derived from the percentage values obtained and the white blood cell count from the same blood sample. Granulocyte and monocyte counts were determined by a routine method using an Advia 120 cytofluorometer (Bayers, Germany).
Statistical methods
Wilcoxon's t-statistics (two-sided) were used for the comparison of independent samples. The Wilcoxon signed-rank test for paired samples was used for comparison between the baseline and end of treatment/follow-up data of laboratory values. This nonparametric test was used due to the highly skewed nature of the laboratory values. The test also considers the intraindividual effect. For the two-by-two crosstable comparisons, Fisher's exact probability test was used. All statistical tests were two-sided and used a P-value of 0.05 for statistical significance. Owing to the exploratory nature of the study, no consideration was made of multiple testing (ie the probability of finding a significant test increases for each test performed).
Results
Clinical effects
A total of 23 patients were available for, and included in, this long-term immunological analysis. The characteristics of the patients are shown in Table 1 . The majority of patients had advanced-stage disease, according to the Rai staging system. 14 The median cumulative dose of alemtuzumab administered was 1363 mg (range 343-1573 mg). All 23 patients responded (CR or partial remission (PR)) and 39% had a CR in the bone marrow. The median time to treatment failure was 26 months (range 8 to 54 þ months). One patient developed cytomegalovirus (CMV) reactivation (fever without pneumonitis, rapidly responding to intravenous ganciclovir) after 4 weeks of therapy; data on immune subpopulations were lacking at this time point. Another patient, who was allergic to cotrimoxazole, developed reversible Pneumocystis carinii pneumonia after 11 weeks of alemtuzumab therapy; the CD4 and CD8 T-cell numbers at the time of infection were 5 and 1 cell/ml, respectively. No opportunistic or other major infections were recorded during long-term, unmaintained follow-up.
Immune populations at baseline
The number of cells within each subpopulation before alemtuzumab therapy in B-CLL patients and age-matched healthy donors is shown in Table 2 . The untreated B-CLL patients had a statistically significant higher total number of cells than the healthy donors for CD4 (Po0.05), CD8 (Po0.01), CD3
À 56 þ NK cells (Po0.01) and CD19 þ 5 À normal B cells (Po0.01). The total numbers of CD52 À CD4 and CD8 T cells, CD3
þ 56 þ NK-T cells, granulocytes and monocytes were not significantly different in the two groups ( Table 2) .
Depletion of immune populations
The reductions in cell numbers within each cell subpopulation during alemtuzumab therapy and follow-up are shown in Figures 1-5. Significant (Po0.001) profound depletions occurred within the CD4 þ ( Figure 1 ) and CD8 þ (Figure 2 ) subsets, which were reduced from median cell counts of 1524 cells/ml (range 215-7564) at baseline to 43 cells/ml (range 5-434) at the end of therapy, and from 1167 cells/ml (range 277-6070) to 20 cells/ml (range 0-1125), respectively. NK cells (CD3 À 56 þ ; Figure 3 ), NK-T cells (CD3 þ 56 þ ; Figure 4 ) and normal (CD19 þ 5 À ) B cells ( Figure 5 ) were also profoundly depletedthe median counts at the end of treatment were, respectively, 4 cells/ml (range 1-8; at baseline: median 553 cells/ml (range 75-4502)); 1 cell/ml (range 0-11; at baseline: 243 cells/ml (range 7-2204)); and 1 cell/ml (range 0-41; at baseline: 825 cells/ml (range 3-20 013)) (Po0.001 for all subsets vs baseline).
Granulocytes and monocytes were also significantly (Po0.01) depleted, from a median of 4.1 Â 10 9 /l (range 0.6-12.6 Â 10 9 /l) at baseline to 2.2 Â 10 9 /l (range 0.7-5.7 Â 10 9 /l) at the end of therapy, and from 0.6 Â 10 9 /l (range 0-7.3 Â 10 9 /l) to 0.1 Â 10 9 /l (range 0-0.7 Â 10 9 /l), respectively. There were no significant differences with regard to lymphocyte depletion between patients who had received a high (4median) cumulative alemtuzumab dose and patients who had received lower doses (pmedian); however, CD4 þ and CD8 þ T-cell counts were numerically lower at the end of therapy in patients who had received higher doses of alemtuzumab (29 cells/ml (range 5-202) for CD4 and 10 cells/ ml (range 1-150) for CD8) than in those who had received lower doses (51 cells/ml (range 5-434) for CD4 and 37 cells/ml (range 1-1125) for CD8).
Immunological recovery
The recovery of each cell population is shown in Figures 1-5 . The recovery was slow and the number of cells within all the lymphoid subpopulations remained significantly lower at multiple time points during unmaintained follow-up than at baseline. There were no significant differences in the recovery pattern between the different lymphoid subsets, except for CD4 þ and CD8 þ cells, for which the proportion of cells in blood (compared with baseline) at þ 6 months was significantly lower than that of monocytes (Po0.05 and ¼ 0.05, respectively). The median time to reach CD4 þ and CD8 þ blood concentrations of 4100 cells/ml was 4 months (Figures 1 and 2 ). The median cell Immune reconstitution after alemtuzumab in B-CLL J Lundin et al counts remained at o25% of baseline levels for all lymphocyte subsets at þ 9 months, with the exception of granulocytes and monocytes. Thereafter, cell numbers increased more rapidly, except for CD19 þ 5 À (normal) B cells, which remained at a low level (albeit based on few observations) at þ 18 months ( Figure 5 ). We then analysed the relationship between the length of immunosuppression for each lymphoid cell population and the cumulative dose of alemtuzumab. Patients who had received a high cumulative dose (4median) had a nonsignificant trend toward a more rapid recovery of CD4 þ and CD8 þ cells than those who received a lower (pmedian) total dose of alemtuzumab (data not shown). There were no differences between the groups with regard to clinical characteristics, response pattern or length of clinical remissions. Granulocyte and monocyte levels were also significantly reduced by treatment, but this reduction was not as pronounced as for the lymphoid cells. Granulocytes returned to baseline levels early during follow-up, while monocytes remained at around 50% of their baseline value for a prolonged period of time.
Immune populations and clinical responses
The relationship between the total number of CD4
À cells, as well as monocytes and granulocytes, and the CR rates was analysed at baseline and during follow-up. There was no statistically significant relationship between the CR rate and the respective 
Figure 2
Time kinetics of the total number of CD8 þ T cells in the blood of B-CLL patients following alemtuzumab treatment. Each box displays the median value and the 25-75% percentiles. n ¼ the number of patients analysed at each time point. P-values refer to the comparison with baseline (Wilcoxon's signed-rank test). BL: baseline; EoT: end of treatment. 
Figure 4
Time kinetics of the total number of CD3 þ 56 þ NK-T cells in the blood of B-CLL patients following alemtuzumab treatment. Each box displays the median value and the 25-75% percentiles. n ¼ the number of patients analysed at each time point. P-values refer to the comparison with baseline (Wilcoxon's signed-rank test). BL: baseline; EoT: end of treatment.
Immune reconstitution after alemtuzumab in B-CLL J Lundin et al cell numbers in these analyses, but patients who achieved a CR in the bone marrow had a significantly lower number of NK cells in the blood at þ 2 months (Po0.05) and þ 4 months (P ¼ 0.06) post-treatment than those who did not reach a CR. No relationship was observed with regard to tumour regression (CR or PR) of the lymph nodes.
CD52
À T cells CD52 À cells occurred in both the CD4 þ and CD8 þ subsets during treatment ( Figure 6 ). The percentage of CD52 À cells was highest at the end of treatment, comprising more than 80% of all CD4 þ and CD8 þ cells. The majority of these cells, when analysed at the end of alemtuzumab treatment, appeared to be truly CD52 À (ie CD52 receptors were not blocked in vivo by alemtuzumab), since double-staining experiments conducted at this time point using anti-CD52 and anti-human Ig monoclonal antibodies revealed no (o0.01%) detectable human/humanised Ig on the cell surface of CD52 À CD4 and CD8 cells (data not shown). Thereafter, the relative proportion of CD52 À cells declined gradually, but these cells were still present at the last ( þ 18 months) analysis, comprising around 25% of all CD4 þ and CD8 þ cells ( Figure 6 ). The total number of CD52 À CD4 and CD8 cells increased during and after alemtuzumab therapy, from medians of 18 cells/ml (range 0-1002) and 22 cells/ml (range 0-1494), respectively, to maximums of 152 cells/ml (range 14-740) and 103 cells/ml (range 6-1174), respectively, at the þ 18 month analysis.
No statistically significant relationship was observed between the CR rates (overall and in bone marrow/lymph nodes) and the total number of CD52 À CD4 and CD8 cells, respectively, during follow-up.
Discussion
Despite being clinically effective, concerns were raised in early trials with regard to the risk of infections associated with alemtuzumab therapy in heavily pretreated patients with advanced B-cell malignancies. 6, 9, 15 The introduction of valaciclovir and cotrimoxazole prophylaxis resulted in a significant reduction, but not elimination, of the risk of serious infections; 5 this risk is assumed to be due mainly to the profound lymphopenia induced by alemtuzumab, in combination with the advanced phase of the disease. 16 Increased knowledge of the length and type of immunosuppression and, in particular, the recovery pattern of the immune system following alemtuzumab treatment is needed. Patients who have received alemtuzumab as first-line therapy (as in the present study) may be ideal candidates for such long-term analysis, since their lymphoid subset numbers are not influenced by prior (purine analog) therapy and they may achieve long-lasting, unmaintained remissions. 9 Another important goal is to correlate changes in immune functions with the clinical effects of antibody therapy.
In the present study, major lymphocyte subpopulations and granulocytes/monocytes in the blood were analysed and correlated with infectious adverse events and clinical response during long-term, unmaintained follow-up in B-CLL patients who had received alemtuzumab s.c. as first-line treatment. The total numbers of T, NK and normal B cells at baseline were significantly higher in patients than in healthy donors. This is in accordance with previous observations in untreated B-CLL patients, 17, 18 verifying the representativeness of our patient material and the robustness of our flow cytometry method. A profound reduction in all lymphoid subsets was observed. The median numbers of CD4 þ and CD8 þ T cells observed at the end of alemtuzumab therapy were similar to those reported by Keating et al 5 in patients with advanced, chemorefractory CLL. In the Keating study, the T-cell counts appeared to increase more rapidly after the end of alemtuzumab therapy than in the present study with previously untreated B-CLL patients, in whom CD4 þ and CD8 þ T cells (as well as the other subpopulations studied) remained suppressed for a long time. The reason for this difference is unclear, but it may be due to the shorter remission durations in advanced CLL than in the present study, since T-cell numbers in the blood may increase in parallel with the progression of CLL. It may be argued that our long-term follow-up results may be influenced by the stepwise withdrawal from the analysis of initially responding patients who developed PD (requiring other therapy) during long-term, unmaintained follow-up. However, no such impact on the results could be observed when such patients, and patients who achieved longlasting remissions, were analysed separately (data not shown). The occurrence of PD during follow-up explains why only few Immune reconstitution after alemtuzumab in B-CLL J Lundin et al patients in our study could be followed for as long as 12-18 months, which limits the statistical power for comparisons between such patients and those who remained in PR/CR. In patients with rheumatoid arthritis, 19 CD4 þ cells remained at o20% of their pretreatment level for 418 months, which is similar to our observations. In contrast, CD8 þ T cells had already recovered to 450% of their pretreatment levels at 2 months, 19 which was clearly faster than in the present study. Immune reconstitution results after stem cell transplantation, using alemtuzumab for graft depletion or to reduce graft-versushost disease (GVHD), indicate that while CD19 þ cell counts normalise relatively quickly and CD8 þ counts either remain stable 20 or recover rapidly, 21 CD4 þ counts may remain subnormal for over a year. 22 It should be noted, however, that the alemtuzumab treatment schedules in patients with rheumatoid arthritis and in those being transplanted differ considerably from those now in use for B-CLL, and in particular from that used in the present study. In addition, NK cells remained profoundly suppressed in our study, which is in contrast to observations after allogeneic transplantation in patients who received alemtuzumab-treated bone marrow, 12, 21 and in rheumatoid arthritis patients treated with alemtuzumab. 19, 23 Importantly, the long-lasting immune suppression in our patients was not associated with any late-occurring infectious complications or autoimmune phenomena, 23 either in the subset of 23 patients reported here or in the total study population (n ¼ 41). 9 This is most likely explained by the fact that our patients were previously untreated, in combination with the high-quality remissions that most of them achieved. The rapid recovery of the granulocyte count may also have contributed to the low rate of infections, as well as the finding that the CD4 þ T-cell count increased to 4100 cells/ml in many patients within a few months following the end of alemtuzumab treatment. Notably, a high incidence of CMV disease, which was inversely correlated with the CD4 þ T-cell count, was reported in patients who received alemtuzumab after nonmyeloablative stem cell transplantation. 22 This is in line with observations in B-CLL patients, in whom almost all CMV reactivations occur while patients are still receiving alemtuzumab treatment; 5, 9 this corresponds with the observation that the nadirs in CD4 þ and CD8 þ counts are recorded after approximately 4 weeks of therapy, after which the T-cell count starts to rise, despite continued alemtuzumab administration. 5 Nadir lymphoid subset counts during alemtuzumab treatment were not recorded in the present study. An increasing CD4 þ T-cell count per se does not, however, guarantee a functioning T-cell system, as the T-cell repertoire may be severely skewed for a long time after alemtuzumab treatment (ie most polyclonal T cells may remain severely suppressed). 13 Whether CD52 À T cells [11] [12] [13] are functionally intact and compensate for the loss of CD52 þ T cells remains to be shown. Preliminary data from our laboratory indicate that the T-cell response to a recall antigen (PPD) and a mitogen (PHA) is suppressed, but not severely, when analysed at þ 3 months following the end of alemtuzumab therapy and compared to a control group consisting of untreated B-CLL patients (data not shown). Furthermore, observations in patients with multiple sclerosis have revealed that the lymphocyte pool may be reconstituted with cells that exhibit decreased mitogen-induced proliferation and interferon-g secretion. 24 In the present study, there was no significant relationship between the cumulative dose of alemtuzumab and the severity or length of the depletion of each lymphocyte subpopulation. Even though the moderate number of patients in our study limits the statistical power to detect such differences, it should be noted that patients receiving a high cumulative dose of alemtuzumab (4median) had a nonsignificant tendency toward lower CD4
þ and CD8 þ cell numbers at the end of treatment, but also more rapid regeneration, than those who had received lower doses. The reason for this is unknown. No between-group differences were observed with regard to clinical characteristics, length of therapy and response/relapse pattern. Similar results were observed in patients with advanced B-CLL receiving alemtuzumab therapy (M Keating, personal communication). This corresponds, at least partly, with the observations from studies of autoimmune disorders, in which CD4 þ T cells were depleted for a long time despite very low doses of alemtuzumab being administered. [19] [20] [21] [22] [23] It is possible that once a certain dose of alemtuzumab has been reached, additional dosing will not further increase the length of immunosuppression. This may be important in future trials with high doses of alemtuzumab as well as in the allogeneic transplantation setting in studies using reduced doses of alemtuzumab to determine the optimal balance between the reduction of GVHD and immune reconstitution. 22 Another important issue is the link between immunological variables and the clinical effects following antibody therapy. Recently, a significant correlation was demonstrated in lowgrade lymphoma patients between clinical response to combined rituximab/interleukin-2 therapy and high NK cell counts post-therapy (Hurst D et al. J Clin Oncol 2002; 21: 283a; abstract). A similar relationship was not observed in the present study, although a significant correlation between low posttreatment NK cell numbers and the achievement of a CR in the bone marrow was observed. The importance of such statistical relationships, either for prediction of response or during/ following therapy, remain unclear, and further in vivo studies are warranted to investigate the complex relationship between various immune effector functions and the clinical effects of monoclonal antibody therapy. Except for the correlation between NK cell numbers and CRs in the bone marrow, no other correlations were observed in our study between the immune reconstitution pattern and the clinical outcomes.
In conclusion, this study has demonstrated that treatment with alemtuzumab as first-line therapy in B-CLL patients is associated with a nondose-dependent, long-lasting depletion of major blood lymphocyte subsets, which was not associated with lateoccurring infections or the emergence of autoimmune phenomena, but was paralleled by increased numbers of CD52 À CD4 and CD8 T cells.
